LitAlert ~~ GeneLit.com

    • Clinical presentation, diagnosis and management of Therapy-Related Hematological Disorders in Women with Epithelial Ovarian Cancer treated with Chemotherapy and Poly-ADP-Ribose Polymerase Inhibitors (PARP-i): a single Center experience.
    • Todisco E, Gigli F, Mantiero M, Sammassimo S, Pastano R, Ronchini C, Parma G, Lapresa MT, Iori AP, Bertolini F, Corsini C, Gregato G, Poletti C, Colombo N, Tarella C.
    • Int J Cancer. 2020 Aug 28. doi: 10.1002/ijc.33269. [Epub ahead of print]
    • Study: Among women with breast cancer, who should have genetic testing for an inherited mutation?
    • [No author given]
    • FORCE. XRAYS. 2020 Aug 27.

    Original research:

    Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.

    • Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.
    • Gonzalez R, Havrilesky LJ, Myers ER, Secord AA, Dottino JA, Berchuck A, Moss HA.
    • Gynecol Oncol. 2020 Aug 27. pii: S0090-8258(20)33759-8. doi: 10.1016/j.ygyno.2020.08.003. [Epub ahead of print]
    • Impact of a Cancer Gene Variant Reclassification Program Over a 20-Year Period.
    • Esterling L, Wijayatunge R, Brown K, Morris B, Hughes E, Pruss D, Manley S, Bowles KR, Ross TS.
    • JCO Precis Oncol. 2020;4:944. doi: 10.1200/PO.20.00020. Epub 2020 Aug 27.
    • Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    • Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK.
    • Lancet Oncol. 2020 Aug 27:S1470-2045(20)30447-2. doi: 10.1016/S1470-2045(20)30447-2. Epub ahead of print.

    Comment:

    BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?

    • The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
    • Colombo N, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Meunier J, Cameron T, Maloney L, Goble S, Bedel J, Ledermann JA, Coleman RL.
    • Gynecol Oncol. 2020 Aug 26. pii: S0090-8258(20)31130-6. doi: 10.1016/j.ygyno.2020.05.045. [Epub ahead of print]